97 related articles for article (PubMed ID: 28246043)
21. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms.
Tan Y; Ng Q; Jia Q; Kwang J; He F
J Virol; 2015 Apr; 89(7):3712-22. PubMed ID: 25609802
[TBL] [Abstract][Full Text] [Related]
22. Isocyanides as Influenza A Virus Subtype H5N1 Wild-Type M2 Channel Inhibitors.
Wu S; Huang J; Gazzarrini S; He S; Chen L; Li J; Xing L; Li C; Chen L; Neochoritis CG; Liao GP; Zhou H; Dömling A; Moroni A; Wang W
ChemMedChem; 2015 Nov; 10(11):1837-45. PubMed ID: 26506405
[TBL] [Abstract][Full Text] [Related]
23. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
[TBL] [Abstract][Full Text] [Related]
24. Incorporation of privileged structures into 3-O-β-chacotriosyl ursolic acid can enhance inhibiting the entry of the H5N1 virus.
Li H; Chen L; Li S; Liao Y; Wang L; Liu Z; Liu S; Song G
Bioorg Med Chem Lett; 2019 Sep; 29(18):2675-2680. PubMed ID: 31371135
[TBL] [Abstract][Full Text] [Related]
25. Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses.
Li IW; Chan KH; To KW; Wong SS; Ho PL; Lau SK; Woo PC; Tsoi HW; Chan JF; Cheng VC; Zheng BJ; Chen H; Yuen KY
J Clin Virol; 2009 Dec; 46(4):325-30. PubMed ID: 19801200
[TBL] [Abstract][Full Text] [Related]
26. Rhodamine B-based fluorescent probes for molecular mechanism study of the anti-influenza activity of pentacyclic triterpenes.
Li M; Yuan L; Chen Y; Ma W; Ran F; Zhang L; Zhou D; Xiao S
Eur J Med Chem; 2020 Nov; 205():112664. PubMed ID: 32755747
[TBL] [Abstract][Full Text] [Related]
27. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.
Zanin M; Keck ZY; Rainey GJ; Lam CY; Boon AC; Rubrum A; Darnell D; Wong SS; Griffin Y; Xia J; Webster RG; Webby R; Johnson S; Foung S
J Virol; 2015 Apr; 89(8):4549-61. PubMed ID: 25673719
[TBL] [Abstract][Full Text] [Related]
28. Fab MAbs specific to HA of influenza virus with H5N1 neutralizing activity selected from immunized chicken phage library.
Pitaksajjakul P; Lekcharoensuk P; Upragarin N; Barbas CF; Ibrahim MS; Ikuta K; Ramasoota P
Biochem Biophys Res Commun; 2010 May; 395(4):496-501. PubMed ID: 20382115
[TBL] [Abstract][Full Text] [Related]
29. A "building block" approach to the new influenza A virus entry inhibitors with reduced cellular toxicities.
Lin D; Li F; Wu Q; Xie X; Wu W; Wu J; Chen Q; Liu S; He J
Sci Rep; 2016 Mar; 6():22790. PubMed ID: 26952867
[TBL] [Abstract][Full Text] [Related]
30. Influenza virus M2 protein ion channel activity helps to maintain pandemic 2009 H1N1 virus hemagglutinin fusion competence during transport to the cell surface.
Alvarado-Facundo E; Gao Y; Ribas-Aparicio RM; Jiménez-Alberto A; Weiss CD; Wang W
J Virol; 2015 Feb; 89(4):1975-85. PubMed ID: 25473053
[TBL] [Abstract][Full Text] [Related]
31. Theoretical studies of the interaction between influenza virus hemagglutinin and its small molecule ligands.
Song D; Xu H; Liu S
J Mol Model; 2013 Dec; 19(12):5561-8. PubMed ID: 24253319
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors.
Yu Y; Tang Q; Xu Z; Li S; Jin M; Zhao Z; Dong C; Wu S; Zhou HB
Eur J Med Chem; 2018 Nov; 159():206-216. PubMed ID: 30292897
[TBL] [Abstract][Full Text] [Related]
33. Development of anti-influenza A compounds: a pilot study.
Zheng BJ; Chan CS; Poon KM; Ng F; Ho CM; Che CM; Yuen KY
Hong Kong Med J; 2013 Jun; 19 Suppl 4():36-8. PubMed ID: 23775185
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationships of 3-O-β-chacotriosyl ursolic acid derivatives as novel H5N1 entry inhibitors.
Song G; Shen X; Li S; Li Y; Liu Y; Zheng Y; Lin R; Fan J; Ye H; Liu S
Eur J Med Chem; 2015 Mar; 93():431-42. PubMed ID: 25728024
[TBL] [Abstract][Full Text] [Related]
35. PA-X decreases the pathogenicity of highly pathogenic H5N1 influenza A virus in avian species by inhibiting virus replication and host response.
Hu J; Mo Y; Wang X; Gu M; Hu Z; Zhong L; Wu Q; Hao X; Hu S; Liu W; Liu H; Liu X; Liu X
J Virol; 2015 Apr; 89(8):4126-42. PubMed ID: 25631083
[TBL] [Abstract][Full Text] [Related]
36. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
[TBL] [Abstract][Full Text] [Related]
37. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice.
Zhou H; Jin M; Yu Z; Xu X; Peng Y; Wu H; Liu J; Liu H; Cao S; Chen H
Antiviral Res; 2007 Nov; 76(2):186-93. PubMed ID: 17719657
[TBL] [Abstract][Full Text] [Related]
38. New influenza A Virus Entry Inhibitors Derived from the Viral Fusion Peptides.
Wu W; Lin D; Shen X; Li F; Fang Y; Li K; Xun T; Yang G; Yang J; Liu S; He J
PLoS One; 2015; 10(9):e0138426. PubMed ID: 26382764
[TBL] [Abstract][Full Text] [Related]
39. Pentacyclic triterpenes grafted on CD cores to interfere with influenza virus entry: A dramatic multivalent effect.
Xiao S; Si L; Tian Z; Jiao P; Fan Z; Meng K; Zhou X; Wang H; Xu R; Han X; Fu G; Zhang Y; Zhang L; Zhou D
Biomaterials; 2016 Feb; 78():74-85. PubMed ID: 26686050
[TBL] [Abstract][Full Text] [Related]
40. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
